Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrointestinal Behaviour of EDP1815 Oral Dosage Forms
NCT05066373Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EDP1815 in psoriasis and atopic dermatitis (AD) (3 arms), sponsored by Evelo Biosciences. Primary endpoints: Time to onset of radiolabel release at 12 hours and Site of onset of radiolabel release at 12 hours. Started Aug 2021; status: completed.
02
Drugs
EDP1815
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05066373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066373.